Companies Open to US Manufacturing Based on Strategic Value
Torrent Pharma, the flagship company of the Ahmedabad-based Torrent Group, is set to enhance its growth strategy by prioritizing innovation in chronic therapies and expanding into high-growth segments. The company, known for its market-leading vitamin brand Shelcal and cardiac drug Nikoran, aims to leverage its existing strengths while exploring new areas, including weight-loss therapies. With Brazil emerging as a key market alongside India, Torrent Pharma is also considering manufacturing opportunities in the U.S. if they align with long-term strategic goals, according to Aman Mehta, the company’s managing director.
Strategic Acquisitions and Integration Plans
Torrent Pharma has recently made significant strides in its acquisition strategy, with the acquisition of JB Chemicals being one of the largest in its history. This acquisition follows a series of strategic purchases, including Elder Pharma, Unichem, and Curatio over the past several years. The company has received necessary approvals from the Competition Commission of India (CCI) and the Securities and Exchange Board of India (SEBI) for this acquisition. The integration of JB Chemicals into Torrent Pharma is expected to take one to two years, during which the company will focus on understanding the new business landscape and enhancing its capabilities in high-growth areas. The contract development and manufacturing organization (CDMO) segment, which has shown promising potential, will also be a focus area for reinvestment and customer expansion.
Funding the Acquisition
To finance the acquisition of a 46.4% stake in KKR, Torrent Pharma plans to raise approximately ₹12,000 crore through global banks. This funding will cover the acquisition costs and may require additional funds for an open offer, depending on the level of subscription. The company’s approach to financing reflects its commitment to maintaining a robust financial structure while pursuing growth opportunities. The focus on debt financing indicates a strategic decision to leverage financial markets to support its expansion plans without compromising operational stability.
Market Expansion and Future Outlook
Torrent Pharma is keen on expanding its footprint in the U.S. market, which currently accounts for about 10-11% of its revenue, approximately $150 million, and is growing at a rate of 25% this year. The company recognizes the potential for growth in Brazil and Germany as well, with Brazil poised to become a significant market, potentially surpassing the U.S. in the near future. The company’s strategy emphasizes first-to-market launches in key markets, particularly in the chronic disease segment, where there remains a substantial unmet need. Over the next five to ten years, Torrent Pharma aims to increase its innovation output, focusing on chronic therapies that cater to the evolving healthcare landscape.
Commitment to Innovation in Chronic Therapies
As the Indian pharmaceutical industry has largely concentrated on generics, Torrent Pharma is committed to addressing the unmet needs in chronic disease management. The company believes that the current environment is conducive to innovation, with increased investment capabilities compared to previous years. Torrent Pharma plans to prioritize the development of innovative products, particularly in the chronic domain, which is expected to constitute about 70% of its future pipeline. This focus on innovation aligns with the company’s long-term vision of leading the market in chronic therapies and enhancing patient care in India and beyond.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
Follow Us on Twitter, Instagram, Facebook, & LinkedIn
